| - Industry | - Sector | Mr. Fabrice Plasson CEO | XDUS Exchange | FR0011051598 ISIN |
| France Country | 22 Employees | 16 Aug 2018 Last Dividend | - Last Split | - IPO Date |
Amoéba S.A. is a pioneering company, founded in 2010 and headquartered in Chassieu, France, dedicated to the advancement of innovative biological solutions for the control of microbiological risks in a variety of sectors, including water treatment, crop protection, and health. The company's groundbreaking work focuses on the utilization of the amoeba Willaertia magna C2c Maky, exploring its potential to serve as an effective biological biocide. Amoéba S.A.'s pursuit of environmental sustainability and public health safety underpins its mission to develop alternatives to chemical biocides, aiming for solutions that are not only efficacious but also eco-friendly and safe for human use.
Amoéba S.A. specializes in the development of biological biocides designed to mitigate microbiological risks in water systems. Utilizing the natural predation abilities of Willaertia magna C2c Maky, these biocides target harmful bacteria without the use of harmful chemicals, making them a safer and more environmentally friendly option for water treatment facilities, industrial cooling systems, and other applications requiring microbial control.
Expanding the application of its biotechnology, Amoéba S.A. also offers solutions for the agricultural sector. The company's products aim to protect crops from various plant pathogens without the adverse effects of chemical pesticides. This innovative approach not only supports sustainable farming practices but also contributes to the health of ecosystems by reducing chemical runoff and preserving beneficial microorganisms in the soil.
Recognizing the importance of microbial control in health and hygiene, Amoéba S.A. is exploring the use of its biological biocides in the health sector. These applications aim to provide safe, non-toxic methods for controlling harmful bacteria and viruses in medical facilities, public spaces, and potentially in personal care products, offering a new horizon in the prevention of infectious diseases.